Several studies into the pharmacokinetic and pharmacodynamic characteristics of roxadustat among individuals with CKD undergoing HD have demonstrated that roxadustat can transiently elevate endogenous EPO levels, similar to those observed in healthy individuals under hypoxic circumstances, for instance at high altitudes (NCT02965040 in Germany and the United Kingdom; FGCL-4592-039 in the United States) [40,41]. The gene discussed is EPO; the disease is chronic kidney disease.